Terms: = Prostate cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5
1935 results:
1. Risk of Subsequent Primary cancers Among Adult-Onset 5-Year cancer Survivors in South Korea: Retrospective Cohort Study.
Choi YY; Lee M; Kim EH; Lee JE; Jung I; Cheong JH
JMIR Public Health Surveill; 2024 May; 10():e48380. PubMed ID: 38717807
[TBL] [Abstract] [Full Text] [Related]
2. Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors.
Fu XP; Ji CY; Tang WQ; Yu TT; Luo L
Clin Exp Med; 2024 May; 24(1):93. PubMed ID: 38693424
[TBL] [Abstract] [Full Text] [Related]
3. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
4. Analysis of the Gene Networks and Pathways Correlated with Tissue Differentiation in prostate cancer.
Filippi A; Aurelian J; Mocanu MM
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612439
[TBL] [Abstract] [Full Text] [Related]
5. [A single center study:An analysis of the safety and validity of delaying repeated biopsy for patients with atypical small acinar proliferation].
Ji WT; Liu DC; Cui WL; Hu Y; Wang Y; Tan JF
Zhonghua Nan Ke Xue; 2023 May; 29(5):414-419. PubMed ID: 38602757
[TBL] [Abstract] [Full Text] [Related]
6. prostate-Specific Antigen Screening and 15-Year prostate cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract] [Full Text] [Related]
7. Assessment of the accuracy of biparametric MRI/TRUS fusion-guided biopsy for index tumor evaluation using postoperative pathology specimens.
Shimizu R; Morizane S; Yamamoto A; Yamane H; Nishikawa R; Kimura Y; Yamaguchi N; Hikita K; Honda M; Takenaka A
BMC Urol; 2024 Apr; 24(1):79. PubMed ID: 38575912
[TBL] [Abstract] [Full Text] [Related]
8. Evaluating appropriateness of 18F-fluciclovine PET/CT relative to standard of care imaging guidelines and the impact of ADT on positivity: a prospective study in 62 Veterans Administration patients at a single institution.
Green A; Temsah P; Goldfarb L; Sanfolippo K; Knoche E; Muzaffar R; Osman MM
Nucl Med Commun; 2024 Jun; 45(6):526-535. PubMed ID: 38517329
[TBL] [Abstract] [Full Text] [Related]
9. Other-cause mortality in incidental prostate cancer.
Di Bello F; Baudo A; de Angelis M; Jannello LMI; Siech C; Tian Z; Goyal JA; Collà Ruvolo C; Califano G; La Rocca R; Morra S; Acquati P; Saad F; Shariat SF; Carmignani L; de Cobelli O; Briganti A; Chun FKH; Longo N; Karakiewicz PI
Prostate; 2024 Jun; 84(8):731-737. PubMed ID: 38506561
[TBL] [Abstract] [Full Text] [Related]
10. [Net survival analysis of cancer in Zhongshan City of Guangdong Province in China, 1970 to 2014].
Li ZM; Liang ZH; Liu N; Wei KR
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):232-238. PubMed ID: 38494769
[No Abstract] [Full Text] [Related]
11. Significance of the cribriform morphology area ratio for biochemical recurrence in Gleason score 4 + 4 prostate cancer patients following robot-assisted radical prostatectomy.
Shimodaira K; Inoue R; Hashimoto T; Satake N; Shishido T; Namiki K; Harada K; Nagao T; Ohno Y
Cancer Med; 2024 Mar; 13(5):e7086. PubMed ID: 38477506
[TBL] [Abstract] [Full Text] [Related]
12. A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.
Gu J; Chery L; González GMN; Huff C; Strom S; Jones JA; Griffith DP; Canfield SE; Wang X; Huang X; Roberson P; Meng QH; Troncoso P; Ittmann M; Covinsky M; Scheurer M; Irizarry Ramirez M; Pettaway CA
Prostate; 2024 May; 84(7):694-705. PubMed ID: 38477020
[TBL] [Abstract] [Full Text] [Related]
13. High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy.
Lischalk JW; Sanchez A; Santos VF; Mendez C; Akerman M; Carpenter T; Tam M; Byun D; Wise DR; Mahadevan A; Evans A; Huang W; Katz A; Lepor H; Haas JA
Radiat Oncol; 2024 Mar; 19(1):29. PubMed ID: 38439040
[TBL] [Abstract] [Full Text] [Related]
14. Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant prostate cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract] [Full Text] [Related]
15. prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO).
Koerber SA; Höcht S; Aebersold D; Albrecht C; Boehmer D; Ganswindt U; Schmidt-Hegemann NS; Hölscher T; Mueller AC; Niehoff P; Peeken JC; Pinkawa M; Polat B; Spohn SKB; Wolf F; Zamboglou C; Zips D; Wiegel T
Strahlenther Onkol; 2024 Mar; 200(3):181-187. PubMed ID: 38273135
[TBL] [Abstract] [Full Text] [Related]
16. Analyzing cancer Incidence Trends in Oman From 1996 to 2019: A Comprehensive Study of the National cancer Annual Reports.
Al-Sayegh H; Al-Zadjali S; Al-Moundhri M
JCO Glob Oncol; 2024 Jan; 10():e2300337. PubMed ID: 38271648
[TBL] [Abstract] [Full Text] [Related]
17. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Sathekge MM; Lawal IO; Bal C; Bruchertseifer F; Ballal S; Cardaci G; Davis C; Eiber M; Hekimsoy T; Knoesen O; Kratochwil C; Lenzo NP; Mahapane J; Maserumule LC; Mdlophane AH; Mokoala KMG; Ndlovu H; Pant V; Rathke H; Reed J; Sen IB; Singh A; Sood A; Tauber R; Thakral P; Yadav MP; Morgenstern A
Lancet Oncol; 2024 Feb; 25(2):175-183. PubMed ID: 38218192
[TBL] [Abstract] [Full Text] [Related]
18. Variation in patterns of second primary malignancies across U.S. race and ethnicity groups: a Surveillance, Epidemiology, and End Results (SEER) analysis.
McGuire V; Lichtensztajn DY; Tao L; Yang J; Clarke CA; Wu AH; Wilkens L; Glaser SL; Park SL; Cheng I
Cancer Causes Control; 2024 May; 35(5):799-815. PubMed ID: 38206498
[TBL] [Abstract] [Full Text] [Related]
19. Combination of [
Kim J; Lee S; Kim D; Kim HJ; Oh KT; Kim SJ; Choi YD; Giesel FL; Kopka K; Hoepping A; Lee M; Yun M
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1763-1772. PubMed ID: 38200396
[TBL] [Abstract] [Full Text] [Related]
20. Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework.
Jiao B; Carlson JJ; Garrison LP; Basu A
Value Health; 2024 Apr; 27(4):433-440. PubMed ID: 38191022
[TBL] [Abstract] [Full Text] [Related]
[Next]